– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – CAMBRIDGE, Mass. and BEDFORD, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechn ...

Stoke Therapeutics (STOK) 2025 Conference June 04, 2025 01:25 PM ET Speaker0 Yeah. I mean, it truly does differentiate your medicine. Speaker1 Right. Are you ready? Yep. Okay. We're gonna get started with our next session. I'm Andrew Tsai, senior biotech analyst at Jefferies. Thanks for joining me today. It's my pleasure to have Stokes Interim CEO, Ian Smith, by my side today. Welcome, Ian. Speaker0 Thank you, Andrew. Speaker1 Thank you. Yep. And so maybe spend the next couple minutes discussing Stokes, wha ...